Bevacizumab

• Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A).
• Its primary action is to inhibit angiogenesis, thereby cutting off a tumor’s blood supply.
• It is used in combination with chemotherapy for several advanced cancers, including colorectal and lung cancers.
• Common adverse effects include hypertension, proteinuria, and fatigue.
• Careful patient monitoring is crucial due to potential serious side effects like bleeding or gastrointestinal perforations.

What is Bevacizumab?

Bevacizumab is a recombinant humanized monoclonal antibody designed to specifically target and bind to vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that plays a critical role in angiogenesis, the biological process by which new blood vessels form. By binding to VEGF-A, bevacizumab prevents this growth factor from interacting with its receptors on the surface of endothelial cells. This action effectively inhibits the development of new blood vessels that tumors rely on for oxygen and nutrients, thereby hindering their growth and spread. Understanding what is Bevacizumab involves recognizing its role as an anti-angiogenic agent in cancer therapy.

Mechanism of Action and Clinical Applications of Bevacizumab

How does bevacizumab work to exert its anti-cancer effects? Its core mechanism involves the selective neutralization of VEGF-A. Tumors often produce excessive amounts of VEGF-A to stimulate the rapid formation of new blood vessels, creating a robust blood supply to fuel their aggressive growth and facilitate metastasis. By blocking VEGF-A, bevacizumab essentially “starves” the tumor by disrupting this vital blood supply. This inhibition of angiogenesis not only slows tumor growth but can also normalize existing tumor vasculature, potentially enhancing the delivery of co-administered chemotherapy agents.

What is bevacizumab used for in clinical oncology? It is approved for the treatment of several advanced or metastatic cancers, typically administered in combination with standard chemotherapy regimens. Its clinical applications include:

• Metastatic colorectal cancer
• Non-small cell lung cancer (NSCLC), specifically non-squamous histology
• Metastatic renal cell carcinoma
• Glioblastoma, a severe form of brain cancer
• Cervical cancer
• Epithelial ovarian, fallopian tube, or primary peritoneal cancer

These diverse indications underscore its importance in managing various solid tumors where angiogenesis is a key driver of disease progression.

Bevacizumab Side Effects and Important Drug Information

Patients undergoing treatment with bevacizumab side effects may experience various adverse reactions, ranging from mild to severe. Common side effects include hypertension (high blood pressure), proteinuria (excess protein in the urine), fatigue, headache, and diarrhea. More serious, though less frequent, complications can include bleeding events (e.g., gastrointestinal hemorrhage, epistaxis), gastrointestinal perforations, arterial thromboembolic events (such as stroke or myocardial infarction), and impaired wound healing. Due to the risk of compromised wound healing, bevacizumab is typically discontinued prior to and following surgical procedures.

Essential bevacizumab drug information highlights the need for careful patient monitoring and management. It is administered intravenously, usually on a schedule of every two or three weeks, depending on the specific cancer type and treatment protocol. Before initiating therapy, patients are evaluated for pre-existing conditions, particularly cardiovascular health and renal function. Throughout treatment, regular monitoring of blood pressure and urine protein levels is crucial to detect and manage potential adverse effects promptly. Patients are advised to report any signs of unusual bleeding, severe abdominal pain, or symptoms suggestive of a thromboembolic event immediately to their healthcare provider. The decision to prescribe bevacizumab is made by an oncology specialist, carefully weighing the potential therapeutic benefits against the associated risks for each individual patient.